Galectin Therapeutics Stock Market Value
| GALT Stock | USD 2.93 0.15 4.87% |
| Symbol | Galectin |
Is there potential for Stock market expansion? Will Galectin introduce new products? Factors like these will boost the valuation of Galectin Therapeutics. Market participants price Galectin higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Galectin Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galectin Therapeutics is measured differently than its book value, which is the value of Galectin that is recorded on the company's balance sheet. Investors also form their own opinion of Galectin Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Galectin Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Galectin Therapeutics' market value can be influenced by many factors that don't directly affect Galectin Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galectin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galectin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Galectin Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Galectin Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Galectin Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Galectin Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Galectin Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Galectin Therapeutics or generate 0.0% return on investment in Galectin Therapeutics over 90 days. Galectin Therapeutics is related to or competes with DiaMedica Therapeutics, Design Therapeutics, Rocket Pharmaceuticals, Aura Biosciences, Alpha Tau, EnGene Holdings, and LB Pharmaceuticals. Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of thera... More
Galectin Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Galectin Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Galectin Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 39.42 | |||
| Value At Risk | (8.89) | |||
| Potential Upside | 8.89 |
Galectin Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galectin Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Galectin Therapeutics' standard deviation. In reality, there are many statistical measures that can use Galectin Therapeutics historical prices to predict the future Galectin Therapeutics' volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.36) | |||
| Treynor Ratio | 1.7 |
Galectin Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | 1.71 | |||
| Mean Deviation | 4.41 | |||
| Coefficient Of Variation | (682.01) | |||
| Standard Deviation | 6.21 | |||
| Variance | 38.58 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.36) | |||
| Treynor Ratio | 1.7 | |||
| Maximum Drawdown | 39.42 | |||
| Value At Risk | (8.89) | |||
| Potential Upside | 8.89 | |||
| Skewness | (1.33) | |||
| Kurtosis | 5.75 |
Galectin Therapeutics Backtested Returns
Galectin Therapeutics holds Efficiency (Sharpe) Ratio of -0.15, which attests that the entity had a -0.15 % return per unit of risk over the last 3 months. Galectin Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Galectin Therapeutics' Risk Adjusted Performance of (0.1), market risk adjusted performance of 1.71, and Standard Deviation of 6.21 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of -0.54, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Galectin Therapeutics are expected to decrease at a much lower rate. During the bear market, Galectin Therapeutics is likely to outperform the market. At this point, Galectin Therapeutics has a negative expected return of -0.91%. Please make sure to check out Galectin Therapeutics' value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Galectin Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.07 |
Very weak reverse predictability
Galectin Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Galectin Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Galectin Therapeutics price movement. The serial correlation of -0.07 indicates that barely 7.0% of current Galectin Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.07 | |
| Spearman Rank Test | -0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 1.08 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.